Bristol-Myers Squibb Company (BMY) Expected Move

Expected move estimates the probable price range for a given period based on at-the-money options pricing. It reflects the market consensus for volatility over the selected timeframe.

Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $130.12B, listed on NYSE, employing roughly 32,500 people, carrying a beta of 0.23 to the broader market. Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. Led by Christopher S. Boerner, public since 1972-06-01.

Snapshot as of Aug 14, 2026.

Spot Price

$63.97

Expected Move

7.1%

Implied High

$68.51

Implied Low

$59.43

Front DTE

28 days

As of Aug 14, 2026, Bristol-Myers Squibb Company (BMY) has an expected move of 7.09%, a one-standard-deviation implied price range of roughly $59.43 to $68.51 from the current $63.97. Expected move is derived from at-the-money straddle pricing and represents the market's pricing of a ±1σ move. Roughly 68% of outcomes should fall within this range under lognormal assumptions, though empirical markets have fatter tails.

BMY Strategy Sizing to the Expected Move

With Bristol-Myers Squibb Company pricing an expected move of 7.09% from $63.97, risk-defined strategies sized to the implied range structurally target the modal outcome distribution. Iron condors with wings at the ±1σ expected move boundaries collect premium against the ~68% probability that spot stays inside the range under lognormal assumptions; strangles set wider at ±1.5σ or ±2σ target the tails but pay smaller per-trade premium. Long-vol structures (long straddles, ratio backspreads) profit when realized move exceeds the implied move, the inverse trade: they bet against the lognormal assumption itself, capitalizing on the empirically fatter equity-return tails.

How to read the BMY implied-range chart

The shaded range above shows the one-standard-deviation implied price band at each listed expiration, derived from ATM implied volatility scaled to days-to-expiration. The front-tenor expected move is 7.09%, anchoring an implied range of approximately $59.43 to $68.51. Under lognormal assumptions, roughly 68% of outcomes fall inside that band; 95% fall inside ±2σ; 99.7% inside ±3σ. The empirical equity-return distribution has fatter tails than lognormal, so true tail-outcome frequency is moderately higher than these closed-form numbers suggest.

BMY expected move and event pricing

Expected move widens with √time: a 5% 30-day move corresponds to roughly a 2.5% 7.5-day move and a 10% 120-day move. BMY term-structure is in contango (slope 0.001), so longer-dated tenors price in proportionally more vol than √time scaling alone would suggest - typically because long-dated cycles include uncertain macro states. With IV rank at 20.2%, the implied move is at the low end of the typical BMY range - cheap optionality for buyers, thin premium for sellers.

Sizing BMY structures to the expected move

Iron condors with wings at ±1σ collect the modal-outcome premium; ±1.5σ widens probability of inside-range to ~87% but cuts collected premium roughly in half. Strangles do the inverse trade - they pay against the same lognormal distribution, profiting when realized exceeds implied. Calendar spreads bet on the slope of the term structure rather than the level. BMY put/call volume ratio currently at 0.55 indicates speculative call flow dominates - look for upside-skewed sentiment. The expected move is the inputs the chain is pricing, not a forecast - realized moves above or below are normal under any distribution.

Learn how expected move is reported and how to read the data →

Per-expiration expected move for BMY derived from ATM implied volatility at each listed expiration. Implied high/low bounds are computed as $63.97 × (1 ± expected move %). One standard-deviation range under lognormal assumptions, roughly 68% of outcomes fall inside.

Frequently asked BMY expected move questions

What is the current BMY expected move?

As of Aug 14, 2026, Bristol-Myers Squibb Company (BMY) has an expected move of 7.09% over the next 28 days, implying a one-standard-deviation price range of $59.43 to $68.51 from the current $63.97. The expected move is derived from at-the-money straddle pricing and represents the market consensus for a ±1σ price move.

What does the BMY expected move mean for traders?

Roughly 68% of outcomes should fall within ±1 expected move and 95% within ±2 under lognormal assumptions, though equity returns have empirically fatter tails than log-normal predicts. Strategies sized to the expected move (iron condors at ±1σ, strangles at ±1.5σ) target the typical outcome distribution; strategies that profit from tail moves (long-vol structures, ratio backspreads) target the tails the lognormal model under-prices.

How is BMY expected move calculated?

The expected move displayed here is derived from at-the-money implied volatility scaled to the chosen tenor: expected move % is approximately ATM IV times sqrt(T / 365), where T is days to expiration. An equivalent straddle-based form: the ATM straddle (call + put at the same strike) is roughly sqrt(2/pi) times spot times IV times sqrt(T/365), so the implied one-standard-deviation move is approximately 1.25 times ATM straddle divided by spot. The two formulations agree once the sqrt(2/pi) constant is reconciled.